Pharmacogenomics Moves Into Spotlight With Completion Of Genome Project
Executive Summary
Industry is ready to "embrace" pharmacogenomic-based drug development as long as commercial and regulatory applications are based on a full understanding of the technology, AstraZeneca VP-Clinical Development Glenn Gormley, MD/PhD, said during FDA's risk management public workshop April 9
You may also be interested in...
Drug Development Too Risky Without Pharmacogenomics, McClellan Says
The future of drug development is too risky without the use of pharmacogenomics-based therapies, FDA Commissioner McClellan told a Drug Information Association workshop Nov. 13
Drug Development Too Risky Without Pharmacogenomics, McClellan Says
The future of drug development is too risky without the use of pharmacogenomics-based therapies, FDA Commissioner McClellan told a Drug Information Association workshop Nov. 13
Parexel Consulting Business Slowed By Fewer FDA GMP Enforcement Actions
Parexel's manufacturing compliance consulting business has slowed because of fewer FDA good manufacturing practice enforcement actions